Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease

As one of the drugs for treating Mycobacterium abscessus infections, linezolid is effective but its use is limited in anti-Mycobacterium abscessus treatment regimens due to the high incidence of adverse reactions associated with long-term use. Contezolid, a new drug developed in China, belongs to the oxazolidinone class of drugs and shares a similar antibacterial spectrum with linezolid, while exhibiting a significantly better safety profile. This study is a single-center, randomized, controlled, open-label clinical trial designed to evaluate the early bactericidal activity. It enrolls patients with Mycobacterium abscessus disease and administers a 14-day monotherapy of contezolid for the treatment of the disease. The study compares contezolid with linezolid, a classic anti-Mycobacterium abscessus drug, by analyzing colony forming units and Time To Positivity in sputum cultures. By assessing the impact of contezolid monotherapy on the bacterial load in the sputum of patients with Mycobacterium abscessus disease, the study evaluates the early bactericidal activity of contezolid, providing a basis for the selection of new therapeutic options for the treatment of Mycobacterium abscessus disease.

Inclusion criteria

• Male or female aged between 18 and 65 years old;
• Weight ranging from 40 kg to 90 kg;
• At least one positive sputum culture for Mycobacterium abscessus within 6 months prior to screening, and one positive sputum culture for Mycobacterium abscessus with molecular species identification during the screening period within 1 month prior to the study;
• Voluntary participation in this study and signing of the informed consent form; (5) Male and female participants must use effective contraception during the study and for 1 month after the study ends.

Exclusion criteria

• Patients who have been on long-term corticosteroid therapy or taking immunosuppressants within 90 days prior to screening;
• Pregnant women, postpartum women, and lactating patients;
• Patients with a history of bedaquiline allergy or known hypersensitivity, or a history of severe adverse reactions;
• Patients with evidence of bedaquiline resistance;
• Patients deemed unsuitable for participation in this study by the investigator's assessment;
• Patients whom the investigator believes participation in this study would harm their health, or who are unlikely to comply with the scheduled visits and assessments as outlined in the protocol, and therefore are not suitable for participation in this study.